{"id":"NCT02397473","sponsor":"Eli Lilly and Company","briefTitle":"A Study Of Galcanezumab In Participants With Episodic Cluster Headache","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-22","primaryCompletion":"2018-02-12","completion":"2018-06-04","firstPosted":"2015-03-25","resultsPosted":"2019-03-13","lastUpdate":"2019-09-09"},"enrollment":109,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Episodic Cluster Headache"],"interventions":[{"type":"DRUG","name":"Galcanezumab","otherNames":["LY2951742"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Galcanezumab 300mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headaches.","primaryOutcome":{"measure":"Overall Mean Change From Baseline in Number of Weekly Cluster Headache Attacks","timeFrame":"Baseline, Week 1 through Week 3","effectByArm":[{"arm":"Placebo","deltaMin":-5.22,"sd":1.33},{"arm":"Galcanezumab 300mg","deltaMin":-8.69,"sd":1.42}],"pValues":[{"comp":"OG000 vs OG001","p":"0.036"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":47,"countries":["United States","Belgium","Canada","Denmark","Finland","France","Germany","Greece","Italy","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["38162453","34267550","31291515"],"seeAlso":["https://www.lillytrialguide.com/en-US/studies/episodic-cluster-headache/CGAL"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":57},"commonTop":["Nasopharyngitis","Injection site pain","Back pain"]}}